Stocks · News reference

8-K filing — Rein Therapeutics, Inc. (RNTX)

Sep 4, 2026, 8:31 PMSEC EDGAR

Filed: 2026-09-04 AccNo: 0001193125-26-383726 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 4, 2026, 12:02 PMBenzinga Newsdesk
Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a
RNTX
BenzingaAug 20, 2026, 12:02 PMBenzinga Newsdesk
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
RNTX
BenzingaAug 18, 2026, 11:36 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
RNTX